NASDAQ:AMLN

Amylin Pharmaceuticals (AMLN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AMLN stock logo

About Amylin Pharmaceuticals Stock (NASDAQ:AMLN)

Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines. It markets two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. It is also markets a diabetes treatment, BYDUREON (exenatide extended-release for injectable suspension). BYDUREON is an extended-release medication for type 2 diabetes that provides continuous glycemic control in a once-weekly dose. Amylin maintains a research and early development program focused on peptide and protein therapeutics. It has also entered into alliances and business initiatives, including its relationship with Biocon, Limited (Biocon) to develop pharmaceutical products, including AC165198, a peptide hybrid drug candidate for diabetes, which was developed from its phybrid technology platform. In August 2012, Bristol-Myers Squibb Company acquired the Company.

AMLN Stock News Headlines

“Retirement Secret” Showed 995% Gain Last Time We Shared It
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Dion's ETF Winners and Losers: VXX, FBT
How to Value Biotech Stocks
Daniel Bradbury
See More Headlines
Receive AMLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:AMLN
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

AMLN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Amylin Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amylin Pharmaceuticals investors own include Chipotle Mexican Grill (CMG), Booking (BKNG), BlackBerry (BB), Bank of America (BAC), Arena Pharmaceuticals (ARNA), Ariad Pharmaceuticals (ARIA), Alpha Natural Resources (ANRZQ), Amarin (AMRN) and AEGR (AEGR).

This page (NASDAQ:AMLN) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners